Testosterone cypionate is an injectable depot ester of testosterone supplied as an oil solution. U.S. labelling describes replacement therapy for specific congenital or acquired testosterone-deficiency conditions; it does not establish safety or effectiveness for age-related hypogonadism alone.

Established. Review the research and limitations before relying on this record.

After ester hydrolysis, testosterone acts through androgen receptors. In androgen-responsive tissues, testosterone can also be converted to dihydrotestosterone or estradiol; these pathways help explain why effects and risks are not limited to skeletal muscle.

The cypionate ester is dissolved in oil for intramuscular depot administration. Release from the depot and hydrolysis to testosterone depend on the labelled formulation, route, injection site and individual factors; a number quoted for another ester or product should not be transferred automatically.

Evidence and U.S. labelling support testosterone replacement for diagnosed primary or hypogonadotropic hypogonadism. That evidence is not evidence for physique enhancement or for treating non-specific ageing symptoms without confirmed deficiency.

The cited label lists risks including polycythaemia, venous thromboembolism, worsening benign prostatic hyperplasia, possible prostate-cancer risk, oedema, altered lipids and abuse or dependence. It is contraindicated in pregnancy and in people with known or suspected breast or prostate carcinoma; the World Anti-Doping Agency lists anabolic agents as prohibited in sport.

“Oil” is informal gym shorthand, not a pharmacological category. This record describes the cited regulated formulation or animal-drug status only; it is not a protocol, a product-quality endorsement, or a recommendation. Human and veterinary products are not interchangeable.